{
  "success": true,
  "pagesUsed": [
    9,
    10,
    11,
    12,
    13,
    18,
    19,
    20,
    21,
    22,
    25,
    26,
    27,
    28,
    29
  ],
  "modelUsed": "gemini-3-flash-preview",
  "objectivesEndpoints": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Efficacy Objective",
        "text": "To evaluate the efficacy of upadacitinib compared to placebo in subjects with active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to at least 1 bDMARD",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Secondary Efficacy Objectives",
        "text": "To evaluate key secondary efficacy endpoints of upadacitinib versus placebo",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_2",
          "ep_3",
          "ep_4",
          "ep_5",
          "ep_6",
          "ep_7",
          "ep_8",
          "ep_9",
          "ep_10"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Safety Objective",
        "text": "Safety evaluations include adverse event (AE) monitoring, physical examinations, vital sign measurements, electrocardiogram (ECG), and clinical laboratory testing (hematology, chemistry, and urinalysis) as a measure of safety and tolerability for the entire study duration.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_11"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "Pharmacokinetic Objective",
        "text": "Blood samples for assay of upadacitinib and possibly other medications in plasma will be collected at each visit after baseline in Period 1.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_12"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_5",
        "name": "Exploratory Research Objective",
        "text": "Prognostic, surrogate, predictive, and pharmacodynamic biomarkers signatures may be evaluated.",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_13"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Primary Efficacy Endpoint",
        "text": "proportion of subjects achieving ACR20 response at Week 12",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_2",
        "name": "Secondary Efficacy Endpoint 1",
        "text": "Change from baseline in HAQ-DI at Week 12",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_3",
        "name": "Secondary Efficacy Endpoint 2",
        "text": "Static Investigator Global Assessment (sIGA) of Psoriasis of 0 or 1 and at least a 2-point improvement from baseline at Week 16",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_4",
        "name": "Secondary Efficacy Endpoint 3",
        "text": "Psoriasis Area Severity Index (PASI) 75 response at Week 16 (for subjects with ≥ 3% BSA psoriasis at baseline)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_5",
        "name": "Secondary Efficacy Endpoint 4",
        "text": "Change from baseline in SF-36 PCS at Week 12",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_6",
        "name": "Secondary Efficacy Endpoint 5",
        "text": "Change from baseline in FACIT-Fatigue Questionnaire at Week 12",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_7",
        "name": "Secondary Efficacy Endpoint 6",
        "text": "Proportion of subjects achieving Minimal Disease Activity (MDA) at Week 24",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_8",
        "name": "Secondary Efficacy Endpoint 7",
        "text": "Change from baseline in Self-Assessment of Psoriasis Symptoms (SAPS) Questionnaire at Week 16",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_9",
        "name": "Secondary Efficacy Endpoint 8",
        "text": "ACR50/70 response at Week 12",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_10",
        "name": "Secondary Efficacy Endpoint 9",
        "text": "ACR20 response at Week 2",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_11",
        "name": "Safety Endpoints",
        "text": "AEs, physical examination, laboratory assessments, ECG, and vital signs",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_12",
        "name": "Pharmacokinetic Endpoints",
        "text": "population central values and the empirical Bayesian estimates of the individual values of upadacitinib oral clearance (CL/F) and volume of distribution (V/F)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Pharmacokinetic"
      },
      {
        "id": "ep_13",
        "name": "Exploratory Endpoints",
        "text": "nucleic acids, proteins, metabolites, or lipids",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Biomarker"
      }
    ],
    "estimands": [
      {
        "id": "est_1",
        "name": "Primary Efficacy Estimand",
        "populationSummary": "Adult patients with active PsA and inadequate response or intolerance to at least 1 bDMARD (Full Analysis Set) Summary measure: Difference in proportions (Cochran-Mantel-Haenszel test).",
        "analysisPopulationId": "est_1_pop",
        "variableOfInterestId": "ep_1",
        "interventionIds": [
          "est_1_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Treatment discontinuation",
            "text": "Subject discontinues study drug treatment before Week 12",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_2",
            "name": "Rescue medication use",
            "text": "Initiation of rescue therapy for lack of efficacy",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Upadacitinib (15 mg or 30 mg QD) vs Placebo",
        "analysisPopulation": "Adult patients with active PsA and inadequate response or intolerance to at least 1 bDMARD (Full Analysis Set)",
        "variableOfInterest": "Proportion of subjects achieving ACR20 response at Week 12",
        "summaryMeasure": "Difference in proportions (Cochran-Mantel-Haenszel test)"
      },
      {
        "id": "est_2",
        "name": "Secondary Efficacy Estimand - HAQ-DI",
        "populationSummary": "Adult patients with active PsA and inadequate response or intolerance to at least 1 bDMARD (Full Analysis Set) Summary measure: Difference in least squares means (ANCOVA).",
        "analysisPopulationId": "est_2_pop",
        "variableOfInterestId": "ep_2",
        "interventionIds": [
          "est_2_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Treatment discontinuation",
            "text": "Subject discontinues study drug treatment before Week 12",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Upadacitinib (15 mg or 30 mg QD) vs Placebo",
        "analysisPopulation": "Adult patients with active PsA and inadequate response or intolerance to at least 1 bDMARD (Full Analysis Set)",
        "variableOfInterest": "Change from baseline in HAQ-DI at Week 12",
        "summaryMeasure": "Difference in least squares means (ANCOVA)"
      },
      {
        "id": "est_3",
        "name": "Secondary Efficacy Estimand - MDA",
        "populationSummary": "Adult patients with active PsA and inadequate response or intolerance to at least 1 bDMARD (Full Analysis Set) Summary measure: Difference in proportions (Cochran-Mantel-Haenszel test).",
        "analysisPopulationId": "est_3_pop",
        "variableOfInterestId": "ep_7",
        "interventionIds": [
          "est_3_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_3",
            "name": "Mandatory treatment switch",
            "text": "Subjects receiving upadacitinib 30 mg QD switched to 15 mg QD per Protocol Amendment 8",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_4",
            "name": "Lack of efficacy discontinuation",
            "text": "Discontinuation due to failure to demonstrate 20% improvement in TJC/SJC at Week 36",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Upadacitinib (15 mg or 30 mg QD) vs Placebo",
        "analysisPopulation": "Adult patients with active PsA and inadequate response or intolerance to at least 1 bDMARD (Full Analysis Set)",
        "variableOfInterest": "Proportion of subjects achieving Minimal Disease Activity (MDA) at Week 24",
        "summaryMeasure": "Difference in proportions (Cochran-Mantel-Haenszel test)"
      }
    ],
    "summary": {
      "primaryObjectives": 1,
      "secondaryObjectives": 3,
      "exploratoryObjectives": 1,
      "totalEndpoints": 13,
      "totalEstimands": 3
    }
  },
  "rawResponse": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Efficacy Objective",
        "text": "To evaluate the efficacy of upadacitinib compared to placebo in subjects with active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to at least 1 bDMARD",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Secondary Efficacy Objectives",
        "text": "To evaluate key secondary efficacy endpoints of upadacitinib versus placebo",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_2",
          "ep_3",
          "ep_4",
          "ep_5",
          "ep_6",
          "ep_7",
          "ep_8",
          "ep_9",
          "ep_10"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Safety Objective",
        "text": "Safety evaluations include adverse event (AE) monitoring, physical examinations, vital sign measurements, electrocardiogram (ECG), and clinical laboratory testing (hematology, chemistry, and urinalysis) as a measure of safety and tolerability for the entire study duration.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_11"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "Pharmacokinetic Objective",
        "text": "Blood samples for assay of upadacitinib and possibly other medications in plasma will be collected at each visit after baseline in Period 1.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_12"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_5",
        "name": "Exploratory Research Objective",
        "text": "Prognostic, surrogate, predictive, and pharmacodynamic biomarkers signatures may be evaluated.",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_13"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Primary Efficacy Endpoint",
        "text": "proportion of subjects achieving ACR20 response at Week 12",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_2",
        "name": "Secondary Efficacy Endpoint 1",
        "text": "Change from baseline in HAQ-DI at Week 12",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_3",
        "name": "Secondary Efficacy Endpoint 2",
        "text": "Static Investigator Global Assessment (sIGA) of Psoriasis of 0 or 1 and at least a 2-point improvement from baseline at Week 16",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_4",
        "name": "Secondary Efficacy Endpoint 3",
        "text": "Psoriasis Area Severity Index (PASI) 75 response at Week 16 (for subjects with ≥ 3% BSA psoriasis at baseline)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_5",
        "name": "Secondary Efficacy Endpoint 4",
        "text": "Change from baseline in SF-36 PCS at Week 12",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_6",
        "name": "Secondary Efficacy Endpoint 5",
        "text": "Change from baseline in FACIT-Fatigue Questionnaire at Week 12",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_7",
        "name": "Secondary Efficacy Endpoint 6",
        "text": "Proportion of subjects achieving Minimal Disease Activity (MDA) at Week 24",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_8",
        "name": "Secondary Efficacy Endpoint 7",
        "text": "Change from baseline in Self-Assessment of Psoriasis Symptoms (SAPS) Questionnaire at Week 16",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_9",
        "name": "Secondary Efficacy Endpoint 8",
        "text": "ACR50/70 response at Week 12",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_10",
        "name": "Secondary Efficacy Endpoint 9",
        "text": "ACR20 response at Week 2",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_11",
        "name": "Safety Endpoints",
        "text": "AEs, physical examination, laboratory assessments, ECG, and vital signs",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_12",
        "name": "Pharmacokinetic Endpoints",
        "text": "population central values and the empirical Bayesian estimates of the individual values of upadacitinib oral clearance (CL/F) and volume of distribution (V/F)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Pharmacokinetic"
      },
      {
        "id": "ep_13",
        "name": "Exploratory Endpoints",
        "text": "nucleic acids, proteins, metabolites, or lipids",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Biomarker"
      }
    ],
    "estimands": [
      {
        "id": "est_1",
        "name": "Primary Efficacy Estimand",
        "populationSummary": "Adult patients with active PsA and inadequate response or intolerance to at least 1 bDMARD (Full Analysis Set) Summary measure: Difference in proportions (Cochran-Mantel-Haenszel test).",
        "analysisPopulationId": "est_1_pop",
        "variableOfInterestId": "ep_1",
        "interventionIds": [
          "est_1_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Treatment discontinuation",
            "text": "Subject discontinues study drug treatment before Week 12",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_2",
            "name": "Rescue medication use",
            "text": "Initiation of rescue therapy for lack of efficacy",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Upadacitinib (15 mg or 30 mg QD) vs Placebo",
        "analysisPopulation": "Adult patients with active PsA and inadequate response or intolerance to at least 1 bDMARD (Full Analysis Set)",
        "variableOfInterest": "Proportion of subjects achieving ACR20 response at Week 12",
        "summaryMeasure": "Difference in proportions (Cochran-Mantel-Haenszel test)"
      },
      {
        "id": "est_2",
        "name": "Secondary Efficacy Estimand - HAQ-DI",
        "populationSummary": "Adult patients with active PsA and inadequate response or intolerance to at least 1 bDMARD (Full Analysis Set) Summary measure: Difference in least squares means (ANCOVA).",
        "analysisPopulationId": "est_2_pop",
        "variableOfInterestId": "ep_2",
        "interventionIds": [
          "est_2_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Treatment discontinuation",
            "text": "Subject discontinues study drug treatment before Week 12",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Upadacitinib (15 mg or 30 mg QD) vs Placebo",
        "analysisPopulation": "Adult patients with active PsA and inadequate response or intolerance to at least 1 bDMARD (Full Analysis Set)",
        "variableOfInterest": "Change from baseline in HAQ-DI at Week 12",
        "summaryMeasure": "Difference in least squares means (ANCOVA)"
      },
      {
        "id": "est_3",
        "name": "Secondary Efficacy Estimand - MDA",
        "populationSummary": "Adult patients with active PsA and inadequate response or intolerance to at least 1 bDMARD (Full Analysis Set) Summary measure: Difference in proportions (Cochran-Mantel-Haenszel test).",
        "analysisPopulationId": "est_3_pop",
        "variableOfInterestId": "ep_7",
        "interventionIds": [
          "est_3_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_3",
            "name": "Mandatory treatment switch",
            "text": "Subjects receiving upadacitinib 30 mg QD switched to 15 mg QD per Protocol Amendment 8",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_4",
            "name": "Lack of efficacy discontinuation",
            "text": "Discontinuation due to failure to demonstrate 20% improvement in TJC/SJC at Week 36",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Upadacitinib (15 mg or 30 mg QD) vs Placebo",
        "analysisPopulation": "Adult patients with active PsA and inadequate response or intolerance to at least 1 bDMARD (Full Analysis Set)",
        "variableOfInterest": "Proportion of subjects achieving Minimal Disease Activity (MDA) at Week 24",
        "summaryMeasure": "Difference in proportions (Cochran-Mantel-Haenszel test)"
      }
    ]
  }
}